On the back of a number of deals in recent months, mainly in dermatology and after dodging its own $100 billion-plus consumption by Pfizer ($PFE) ... ...read more
Growth Capitalist (https://growthcapitalist.com/2016/09/acquisitive-allergan-buys-micro-cap-nash-biotech-tobira-months-after-trial-miss/)
On the back of a number of deals in recent months, mainly in dermatology and after dodging its own $100 billion-plus consumption by Pfizer ($PFE) ... ...read more